How big is Orthofix Medical, Inc.?

As of Jun 18, Orthofix Medical, Inc. has a market capitalization of 412.18 million and reported net sales of 804.54 million with a net profit of -143.07 million over the latest four quarters.

As of Jun 18, Orthofix Medical, Inc. has a market capitalization of 412.18 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 804.54 million, while the sum of net profit for the same period is -143.07 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 503.12 million and total assets of 893.29 million.

What does Orthofix Medical, Inc. do?

Orthofix Medical, Inc. is a global medical device company specializing in reconstructive and regenerative orthopedic and spine solutions. As of March 2025, it reported net sales of $194 million and a market cap of $412.18 million.

Overview: <BR>Orthofix Medical, Inc. is a global medical device company focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 194 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -53 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 412.18 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.22 <BR>Return on Equity: -29.97% <BR>Price to Book: 0.90<BR><BR>Contact Details: <BR>Address: 3451 Plano Pkwy, LEWISVILLE TX: 75056-9453 <BR>Tel: 1 214 9372000 <BR>Website: http://web.orthofix.com/AboutUs/Pages/Overview.aspx

Should I buy, sell or hold Orthofix Medical, Inc.?

Who are in the management team of Orthofix Medical, Inc.?

As of March 2022, the management team of Orthofix Medical, Inc. includes Independent Chairman Ronald Matricaria, CEO Jon Serbousek, and Independent Directors Jason Hannon, James Hinrichs, Alexis Lukianov, Lilly Marks, and Michael Paolucci. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Orthofix Medical, Inc. includes the following individuals:<BR><BR>- Mr. Ronald Matricaria, who serves as the Independent Chairman of the Board.<BR>- Mr. Jon Serbousek, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Jason Hannon, who is an Independent Director.<BR>- Mr. James Hinrichs, who is also an Independent Director.<BR>- Mr. Alexis Lukianov, serving as an Independent Director.<BR>- Ms. Lilly Marks, who is an Independent Director.<BR>- Mr. Michael Paolucci, who is another Independent Director. <BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Is Orthofix Medical, Inc. overvalued or undervalued?

As of April 30, 2021, Orthofix Medical, Inc. is considered a risky investment due to its negative performance metrics and disappointing stock returns, indicating it is overvalued compared to its peers and the S&P 500.

As of 30 April 2021, the valuation grade for Orthofix Medical, Inc. moved from fair to risky, indicating a deterioration in its investment appeal. The company appears overvalued given its negative performance metrics, including a Price to Book Value of 0.94, an EV to Sales ratio of 0.66, and an EV to EBITDA of -27.66. In comparison to peers, Orthofix's EV to EBITDA ratio of -59.0407 is significantly worse than that of Silk Road Medical, Inc. at -18.1243, highlighting its relative underperformance.<BR><BR>The company's recent stock performance has been disappointing, with a year-to-date return of -11.34% compared to the S&P 500's gain of 12.22%, and a 5-year return of -48.14% against the S&P 500's 96.61%. This further reinforces the notion that Orthofix Medical, Inc. is overvalued in its current state.

Is Orthofix Medical, Inc. technically bullish or bearish?

As of September 19, 2025, Orthofix Medical, Inc. is in a mildly bearish trend, with daily moving averages and monthly indicators signaling weakness, while the stock has underperformed the S&P 500 with a year-to-date return of -14.89% compared to the index's 13.31%.

As of 19 September 2025, the technical trend for Orthofix Medical, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the monthly MACD and Bollinger Bands also showing bearish signals. Although the weekly MACD and KST are bullish, the overall monthly indicators suggest weakness. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a year-to-date return of -14.89% compared to the S&P 500's 13.31%, and a 3-year return of -28.11% versus the S&P 500's 70.89%.